RLMD
Price
$1.65
Change
+$0.14 (+9.27%)
Updated
Sep 18, 04:59 PM (EDT)
Capitalization
54.77M
48 days until earnings call
ZVRA
Price
$7.94
Change
+$0.61 (+8.32%)
Updated
Sep 18 closing price
Capitalization
445.71M
47 days until earnings call
Interact to see
Advertisement

RLMD vs ZVRA

Header iconRLMD vs ZVRA Comparison
Open Charts RLMD vs ZVRABanner chart's image
Relmada Therapeutics
Price$1.65
Change+$0.14 (+9.27%)
Volume$8.96K
Capitalization54.77M
Zevra Therapeutics
Price$7.94
Change+$0.61 (+8.32%)
Volume$2.31M
Capitalization445.71M
RLMD vs ZVRA Comparison Chart in %
Loading...
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RLMD vs. ZVRA commentary
Sep 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLMD is a Buy and ZVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 19, 2025
Stock price -- (RLMD: $1.65 vs. ZVRA: $7.94)
Brand notoriety: RLMD and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLMD: 49% vs. ZVRA: 160%
Market capitalization -- RLMD: $54.77M vs. ZVRA: $445.71M
RLMD [@Biotechnology] is valued at $54.77M. ZVRA’s [@Biotechnology] market capitalization is $445.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLMD’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • RLMD’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, RLMD is a better buy in the long-term than ZVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLMD’s TA Score shows that 7 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • RLMD’s TA Score: 7 bullish, 4 bearish.
  • ZVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RLMD is a better buy in the short-term than ZVRA.

Price Growth

RLMD (@Biotechnology) experienced а +8.55% price change this week, while ZVRA (@Biotechnology) price change was -0.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +38.54%.

Reported Earning Dates

RLMD is expected to report earnings on Nov 06, 2025.

ZVRA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZVRA($446M) has a higher market cap than RLMD($54.8M). RLMD YTD gains are higher at: 217.308 vs. ZVRA (-4.796). ZVRA has higher annual earnings (EBITDA): 36.4M vs. RLMD (-70.52M). ZVRA has more cash in the bank: 203M vs. RLMD (20.6M). RLMD has less debt than ZVRA: RLMD (256K) vs ZVRA (62.3M). ZVRA has higher revenues than RLMD: ZVRA (62M) vs RLMD (0).
RLMDZVRARLMD / ZVRA
Capitalization54.8M446M12%
EBITDA-70.52M36.4M-194%
Gain YTD217.308-4.796-4,531%
P/E RatioN/AN/A-
Revenue062M-
Total Cash20.6M203M10%
Total Debt256K62.3M0%
FUNDAMENTALS RATINGS
RLMD vs ZVRA: Fundamental Ratings
RLMD
ZVRA
OUTLOOK RATING
1..100
2861
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9988
PRICE GROWTH RATING
1..100
3487
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
2850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RLMD's Valuation (35) in the null industry is somewhat better than the same rating for ZVRA (78). This means that RLMD’s stock grew somewhat faster than ZVRA’s over the last 12 months.

RLMD's Profit vs Risk Rating (100) in the null industry is in the same range as ZVRA (100). This means that RLMD’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's SMR Rating (88) in the null industry is in the same range as RLMD (99). This means that ZVRA’s stock grew similarly to RLMD’s over the last 12 months.

RLMD's Price Growth Rating (34) in the null industry is somewhat better than the same rating for ZVRA (87). This means that RLMD’s stock grew somewhat faster than ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (23) in the null industry is significantly better than the same rating for RLMD (100). This means that ZVRA’s stock grew significantly faster than RLMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RLMDZVRA
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSRRX8.89N/A
N/A
Fidelity Strategic Real Return
GMOIX32.23N/A
N/A
GMO International Equity III
PSSJX24.16N/A
N/A
Principal SmallCap S&P 600 Index J
VRTTX564.51N/A
N/A
Vanguard Russell 3000 Index I
NESIX20.37N/A
N/A
Needham Small Cap Growth Institutional

RLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
+9.27%
SYRE - RLMD
36%
Loosely correlated
+1.66%
ENTO - RLMD
36%
Loosely correlated
-1.88%
PRTC - RLMD
31%
Poorly correlated
-0.61%
AVXL - RLMD
31%
Poorly correlated
-1.25%
ZVRA - RLMD
29%
Poorly correlated
+8.32%
More